Levi & Korsinsky has started an investigation into Regeneron Pharmaceuticals for potentially misleading investors about the results of a clinical trial. In March 2026, Regeneron's investor relations VP expressed hope for positive trial outcomes of a drug combination, but by May 16, 2026, the trial failed to meet its primary endpoint, causing the stock to fall sharply. The investigation focuses on whether Regeneron failed to adequately disclose the risks of trial failure. Investors who suffered losses may seek recovery under federal securities laws.
The European Medicines Agency (EMA) has accepted Regeneron Pharmaceuticals' Marketing Authorization Application for Otarmeni (lunsotogene parvec), a gene therapy targeting biallelic OTOF variant-associated hearing loss, for accelerated assessment. Ot...
Regeneron Pharmaceuticals is under investigation by Pomerantz LLP following disappointing Phase 3 trial results for its melanoma treatment, which failed to show significant improvement over existing therapy. The news led to a nearly 10% drop in Regen...
Regeneron's Lynozyfic (linvoseltamab) monotherapy achieved a 100% hematologic complete response in patients with second-line-plus systemic amyloid light chain (AL) amyloidosis in the Phase 1/2 LINKER-AL2 trial. The drug normalized free light chains b...
